Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study

Yuji Nishizaki,Katsumi Miyauchi,Hiroshi Iwata,Teruo Inoue,Atsushi Hirayama,Kazuo Kimura,Yukio Ozaki,Toyoaki Murohara,Kenji Ueshima,Yoshihiro Kuwabara,Sachiko Tanaka-Mizuno,Naotake Yanagisawa,Tosiya Sato,Hiroyuki Daida

American Heart Journal（2023）

引用 13|浏览32

暂无评分

摘要

After this study is completed, we will have further evidence on whether a highly purified EPA is effective in reducing cardiovascular events for secondary prevention or not, as well as whether if EPA/AA ratio is a predictor for future cardiovascular events. This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000012069).

查看译文

关键词

Japan EPA Lipid Intervention Study (JELIS),The Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH),The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT),cardiovascular events,eicosapentaenoic acid,omega-3 polyunsaturated fatty acids

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要